Insertion/deletion plasminogen activator inhibitor 1 and insertion/deletion angiotensin-converting enzyme gene polymorphisms in diabetic retinopathy in type 2 diabetes

Ophthalmologica

Volumn 217, Issue 3, 2003, Pages 219-224

  Globoçnik Petrovič, Mojca ^a   Hawlina, Marko ^a   Peterlin, Borut ^a   Petrovič, Daniel ^b,c  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

^c UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Genetics; Insertion deletion (4G5G) PAI 1 gene polymorphism; Insertion deletion ACE gene polymorphism; Retinopathy; Type 2 diabetes

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; DNA; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGED; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE DURATION; FEMALE; GENE DELETION; GENE INSERTION; GENE LOCATION; GENETIC SUSCEPTIBILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; STATISTICAL SIGNIFICANCE; VISUAL ACUITY;

AGED; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE DELETION; GENE FREQUENCY; GENOTYPE; GLYCINE; HUMANS; MALE; MIDDLE AGED; MUTAGENESIS, INSERTIONAL; ODDS RATIO; PEPTIDYL-DIPEPTIDASE A; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; RISK;

EID: 0345700295     PISSN: 00303755     EISSN: None     Source Type: Journal    
DOI: 10.1159/000068975     Document Type: Article

References (34)

1. Klein R, Klein BEK: Visual disorders in diabetes; in Harris CI, Cowie CC, Stern MP, Boyko EJ, Reiber GE, Bennett PH (eds): Diabetes in America. Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1995, pp 293-338.
2. Klein R, Klein BE, Moss SE, Cruickshanks KJ: Relationship of hyperglycemia to the long-term incidence and progression of diabetic retinopathy. Arch Intern Med 1994;154:2169-2178.
3. Merimee TJ: Diabetic retinopathy. A synthesis of perspectives. N Engl J Med 1990;322:978-983.
4. Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes 1997;46:1829-1839.
5. Grant MB, Spoerri PE, Player DW, Bush DM, Ellis EA, Caballero S, Robison WG: Plasminogen activator inhibitor (PAI)-1 overexpression in retinal microvessels of PAI-1 transgenic mice. Invest Ophthalmol Vis Sci 2000;41:2296-2302.
6. Saksela O, Rifkin DB: Cell-associated plasminogen activation: Regulation and physiological functions. Annu Rev Cell Biol 1988;4:93-126.
7. Henry M, Tregouet DA, Alessi MC, Aillaud MF, Visvikis S, Siest G, Tiret L, Juhan-Vague I: Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: A family study with part of the Stanislas Cohort. Arterioscler Thromb Vasc Biol 1998;18:84-91.
8. Juhan-Vague I, Roul C, Alessi MC, Ardissone JP, Heim M, Vague P: Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients - relationship with plasma insulin. Thromb Haemost 1989;61:370-373.
9. Dawson S, Hamsten A, Wiman B, Henney A, Humphries S: Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb 1991;11:183-190.
10. Stegnar M, Uhrin P, Peternel P, Mavri A, Salobir-Pajnic B, Stare J, Binder BR: The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: Relationship to plasma PAI-1 level in venous thromboembolism. Thromb Haemost 1998;79:975-979.
11. Kimura H, Gejyo F, Suzuki Y, Suzuki S, Miyazaki R, Arakawa M: Polymorphisms of angiotensin converting enzyme and plasminogen activator inhibitor-1 genes in diabetes and macroangiopathy. Kidney Int 1998;54:1659-1669.
12. Lonchampt M, Pennel L, Duhault J: Hyperoxia/normoxia-driven retinal angiogenesis in mice: A role for angiotensin II. Invest Ophthalmol Vis Sci 2001;42:429-432.
13. Danser AH, van den Dorpel MA, Deinum J, Derkx FH, Franken AA, Peperkamp E, de Jong PT, Schalekamp MA: Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J Clin Endocrinol Metab 1989;68:160-167.
14. Danser AH, Derkx FH, Admiraal PJ, Deinum J, de Jong PT, Schalekamp MA: Angiotensin levels in the eye. Invest Ophthalmol Vis Sci 1994;35:1008-1018.
15. Paquet JL, Baudouin-Legros M, Brunelle G, Meyer P: Angiotensin II-induced proliferation of aortic myocytes in spontaneously hypertensive rats. J Hypertens 1990;8:565-572.
16. Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE: Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 1993;87:1969-1973.
17. Feener EP, Northrup JM, Aiello LP, King GL: Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. J Clin Invest 1995;95:1353-1362.
18. Brown NJ, Murphey LJ, Srikuma N, Koschachuhanan N, Williams GH, Vaughan DE: Interactive effect of PAI-1 4G/5G genotype and salt intake on PAI-1 antigen. Arterioscler Thromb Vasc Biol 2001;21:1071-1077.
19. Otani A, Takagi H, Suzuma K, Honda Y: Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Circ Res 1998;82:619-628.
20. Seo MS, Kwak N, Ozaki H, Yamada H, Okamoto N, Yamada E, Fabbro D, Hofmann F, Wood JM, Campochiaro PA: Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor. Am J Pathol 1999;154:1743-1753.
21. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F: An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990;86:1343-1346.
22. Costerousse O, Allegrini J, Lopez M, Alhenc-Gelas F: Angiotensin 1-converting enzyme in human circulating mononuclear cells: Genetic polymorphism of the expression in T-lymphocytes. Biochem J 1993;290:33-40.
23. Fujisawa T, Ikegami H, Kawaguchi Y, Hamada Y, Ueda H, Shintani M, Fukuda M, Ogihara T: Meta-analysis of association of insertion/deletion polymorphism of angiotensin I-converting enzyme gene with diabetic nephropathy and retinopathy. Diabetologia 1998;41:47-53.
24. Wong TY, Poon P, Szeto CC, Chan JC, Li PK: Association of plasminogen activator inhibitor-1 4G/4G genotype and type 2 diabetic nephropathy in Chinese patients. Kidney Int 2000;57:632-638.
25. Diabetes mellitus. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1985;727:1-113.
26. Grading diabetic retinopathy from stereoscopic color fundus photographs - an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991;98(5 suppl):786-806.
27. Mansfield MW, Stickland MH, Grant PJ: Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non-insulin-dependent diabetes mellitus. Thromb Haemost 1995;74:842-847.
28. Rigat B, Hubert C, Corvol P, Soubrier F: PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). Nucleic Acids Res 1992;20:1433.
29. Ashton N: Vascular basement membrane changes in diabetic retinopathy. Montgomery lecture, 1973. Br J Ophthalmol 1974;58:344-366.
30. Tarnow L, Stehouwer CD, Emeis JJ, Poirier O, Cambien F, Hansen BV, Parving HH: Plasminogen activator inhibitor-1 and apolipoprotein E gene polymorphisms and diabetic angiopathy. Nephrol Dial Transplant 2000;15:625-630.
31. Nagi DK, McCormack LJ, Mohamed-Ali V, Yudkin JS, Knowler WC, Grant PJ: Diabetic retinopathy, promoter (4G/5G) polymorphism of PAI-1 gene, and PAI-1 activity in Pima Indians with type 2 diabetes. Diabetes Care 1997;20:1304-1309.
32. Marre M, Bernadet P, Gallois Y, Savagner F, Guyene TT, Hallab M, Cambien F, Passa P, Alhenc-Gelas F: Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. Diabetes 1994;43:384-388.
33. Rabensteiner D, Abrahamian H, Irsigler K, Hermann KM, Kiener HP, Mayer G, Kaider A, Prager R: ACE gene polymorphism and proliferative retinopathy in type 1 diabetes: Results of a case-control study. Diabetes Care 1999;22: 1530-1535.
34. Kanauchi M, Kawano T, Uyama H, Shiiki H, Dohi K: Discordance between retinopathy and nephropathy in type 2 diabetes. Nephron 1998;80:171-174.